What's in Roxane Laboratories's pipeline?

Roxane Laboratories has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Roxane Laboratories's portfolio?

Top competitors by shared drug class: , Aarxion Anda Hlding, Cosette, Daiichi Sankyo, Direct_Rx.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/roxane-laboratories.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Roxane Laboratories — Portfolio Competitive Intelligence Brief

Roxane Laboratories pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Avapro	Avapro	marketed			Other
Irbesartan and Hydrochlorothiazide	Irbesartan and Hydrochlorothiazide	marketed	Thiazide Diuretic [EPC]	AT1 angiotensin II receptor
Avalide	Avalide	marketed			Other

Therapeutic area mix

Other · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Aarxion Anda Hlding · 1 shared drug class
Cosette · 1 shared drug class
Daiichi Sankyo · 1 shared drug class
Direct_Rx · 1 shared drug class
Generic (originally Merck) · 1 shared drug class
Generic (originally Merck/AstraZeneca) · 1 shared drug class
Takeda · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Roxane Laboratories:

Cite this brief

Drug Landscape (2026). Roxane Laboratories — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/roxane-laboratories. Accessed 2026-05-13.